To this regard, available lymphoma treatments with an immunomodulatory action are effective in improving pruritus in these patients and have been shown to concurrently reduce IL-31: traditional treatments include corticosteroids, interferons, bexarotene, and photopheresis, while targeted therapeutics consist in histone deacetylase inhibitors and in the anti-CCR4 monoclonal antibody mogamulizumab [65]. Here, IL31 is linked to lymphoma.